Author | Charles F. Shaefer Jr, MD

Articles

Type 2 Diabetes and Medication Adherence: Where is the Disconnect?

September 10, 2013

Incretin drugs, which offer ease of use, very little hypoglycemia, and no weight gain (or even weight loss) seem to be an ideal therapy. But 80% to 90% of patients don’t stay on them. Why not?

The Safety of Incretin Therapy: Are Barriers Beginning to Fall?

August 02, 2013

Incretin-based T2DM therapy is not a direct cause of pancreatitis or pancreatic cancer asserts the European Medicines Agency.

Fix Fasting (Glucose) First, But What About PPG?

July 25, 2013

GLP-1 receptor antagonists suppress post-meal glucose excursions and are compatible with basal insulin; the combination addresses both FPG and PPG.

ADA Take-Aways: Assail Obesity, Stay the Course With Incretins

June 26, 2013

Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.

ADA: SGLT2 Inhibitors Match GLP-1 RAs for A1c Reduction, Weight Loss

June 25, 2013

Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.

On-Site at the ADA: Initial Triple Therapy for T2DM?

June 24, 2013

Initial triple-agent therapy for type 2 diabetes, compared with step-wise add-on therapy, produced a durable drop in A1C.

On Site at the ADA: Insulin and Incretins Take Center Stage

June 24, 2013

Combination therapy that addresses both fasting and post-meal glucose elevation is the next big thing in T2DM management.

On Site at the ADA: Obesity and T2DM

June 24, 2013

Obesity and kidney disease need to be aggressively managed in patients with type 2 diabetes mellitus.